Monday, September 21, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1semaglutideorforglipronnovo nordiskeli lilly

Indirect comparison favors oral semaglutide over orforglipron on weight loss

Pharmacy Times reports the two oral incretins have not been tested head to head, leaving the comparison dependent on modeling across separate trials.

MH
By Maren Holt · Senior Reporter, GLP-1
Apr 6 03:00 ETSource: Pharmacy Times

The wire

  1. 01An indirect treatment comparison found greater weight loss with oral semaglutide than with orforglipron, according to Pharmacy Times.
  2. 02Pharmacists and prescribers weighing the two oral options now have a comparative signal, though it does not carry the weight of a randomized head-to-head.
  3. 03Indirect comparisons depend on matched trial populations and endpoints; a direct trial would be needed to confirm any efficacy gap.

From the source

Oral Semaglutide Demonstrates Greater Weight Loss vs Orforglipron in Indirect Comparison

Read at pharmacytimes.com
Source URL https://www.pharmacytimes.com/view/oral-semaglutide-demonstrates-greater-weight-loss-versus-orforglipron-in-indirect-comparison